Chloroquine and hydroxychloroquine in COVID 19

Document Type : Brief Communication

Authors
M. Pourgholami
M. tavakoli
Department of Physiology, Faculty of Medical sciences, Tarbiat Modares University, Tehran, Iran.
Abstract
Since the emergence of the novel SARS-CoV-2 coronavirus in December 2019, various drugs have been proposed as antiviral agents for treating the coronavirus disease-2019 (COVID-19) patients. Among the very first drugs to be utilized in the clinic were the aminoquinolines chloroquine and hydroxychloroquine (HCQ). At the time this work started, the US FDA and EU EMA had given emergency approval for the use of chloroquine and HCQ in COVID-19 patients. Chloroquine and HCQ have been commonly used for treating malaria and various autoimmune diseases. Additionally, both drugs have been shown to exert other therapeutic effects, including antiviral effects against SARS and MERS causing viruses. The exact antiviral mode of action of Chloroquine and HCQ is unclear even though these drugs exert a broad range of antiviral effects. HCQ is classically considered as an inhibitor of endocytic pathways through elevation of endosomal pH, its detailed molecular mechanisms of action as an antiviral compound remains elusive In-vitro studies show that both drugs can block the viral replication of SARS-CoV- 2 in cell cultures, but a high-level assessment suggested that calculated extracellular lung concentrations are well below the in vitro efficacy values and therefore the drug has low potential for in vivo activity at standard dosing regimens.

Keywords

Subjects

Literature Cited
1. Ahmed SF, Quadeer AA, McKay MR. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses 2020; 12(3).
2. Saha P, Banerjee AK, Tripathi PP, Srivastava AK, Ray U. A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity. Biosci Rep 2020; 40(5).
3. Bernstein KE, Khan Z, Giani JF, Cao D-Y, Bernstein EA, Shen XZ. Angiotensin-converting enzyme in innate and adaptive immunity. Nat Rev Nephrol 2018; 14(5):325–36.
4. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: From Malaria to Autoimmunity. Clinic Rev Allerg Immunol 2012; 42(2):145–53.
5. Sullivan DJ, Gluzman IY, Russell DG, Goldberg DE. On the molecular mechanism of chloroquine's antimalarial action. Proc Natl Acad Sci U S A 1996; 93(21):11865–70.
6. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020; 55(4):105932.
7. Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 2015; 23(5):231–69.
8. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020; 16(3):155–66.
9. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14(1):72–3.
10. Izoulet M. Countries which Primarily Use Antimalarial Drugs As COVID-19 Treatment See Slower Dynamic of Daily Deaths. SSRN Journal 2020.
11. Fantini J, Di Scala C, Chahinian H, Yahi N. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents 2020; 55(5):105960.
12. Baidya A. Relevance and Role of Hydroxychloroquine in Prophylaxis and Therapy of COVID-19. jmscr 2020; 08(04).
13. Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020; 55(5):105938.
14. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71(15):732–9.
15. Gautret P, Lagier J-C, Parola P, van Hoang T, Meddeb L, Sevestre J et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis 2020; 34:101663.
16. Taccone FS, Gorham J, Vincent J-L. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. The Lancet Respiratory Medicine 2020; 8(6):539–41.
17. Mitjà O, Corbacho-Monné M, Ubals M, Tebe C, Peñafiel J, Tobias A et al. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. Clin Infect Dis 2020.
18. Maisonnasse P, Guedj J, Contreras V, Behillil S, Solas C, Marlin R et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature 2020.
19. Mégarbane B. Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution. Clin Toxicol (Phila) 2020:1–2.
20. Gbinigie K, Frie K. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. BJGP Open 2020; 4(2).
Pathobiology Reserach
Volume 23, Issue 0
March 2021
Pages 83-88